{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:40:25Z","timestamp":1760182825663,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.rdc.2018.03.007","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T18:22:41Z","timestamp":1528827761000},"page":"489-499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Crystal-Induced Arthritides in the Elderly"],"prefix":"10.1016","volume":"44","author":[{"given":"Hossam","family":"El-Zawawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian F.","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2018.03.007_bib1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2018.03.007_bib2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","article-title":"Suboptimal physician adherence to quality indicators for the management of gout and Rheumatology asymptomatic hyperuricemia: results from the UK General Practice Research Database (GPRD)","volume":"44","author":"Mikuls","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2018.03.007_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/bmj.1.5851.449","article-title":"Effect of oestrogen therapy on plasma and urinary levels of uric acid","volume":"1","author":"Nicholls","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.rdc.2018.03.007_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10067-014-2520-7","article-title":"The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort","volume":"33","author":"Duskin-Bitan","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2018.03.007_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.03.007_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/M14-2070","article-title":"Oral prednisolone in the treatment of acute gout","volume":"164","author":"Rainer","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2018.03.007_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002512-199813030-00006","article-title":"Gout in the elderly. Clinical presentation and treatment","volume":"13","author":"Fam","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.rdc.2018.03.007_bib8","first-page":"721","article-title":"A\u00a0comparison of gout in men and women: a 10-year experience","volume":"70","author":"Meyers","year":"1986","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.rdc.2018.03.007_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MAJ.0b013e3181a3dc14","article-title":"Axial gouty arthropathy","volume":"338","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.rdc.2018.03.007_bib10","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3899\/jrheum.111517","article-title":"Correlates of axial gout: a cross-sectional study","volume":"39","author":"Konatalapalli","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2018.03.007_bib11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3899\/jrheum.110916","article-title":"Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial","volume":"39","author":"Schumacher","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2018.03.007_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0049-0172(90)90070-V","article-title":"Systemic steroid therapy for acute gout: a clinical trial and review of the literature","volume":"19","author":"Groff","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.03.007_bib13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2018.03.007_bib14","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/acr.21989","article-title":"Treatment of acute gouty arthritis in complex hospitalized patients with anakinra","volume":"65","author":"Ghosh","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2018.03.007_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semarthrit.2015.02.006","article-title":"Anakinra for the treatment of acute severe gout in critically ill patients","volume":"45","author":"Thueringer","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.03.007_bib16","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","article-title":"Colchicine myopathy and neuropathy","volume":"316","author":"Kuncl","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2018.03.007_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study","volume":"41","author":"Hung","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2018.03.007_bib18","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence based colchicine dose reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.03.007_bib19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1681\/ASN.V115974","article-title":"Renal transplant-associated hyperuricemia and gout","volume":"11","author":"Clive","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2018.03.007_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12937-015-0032-1","article-title":"Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Troms\u00f8 study","volume":"14","author":"Zykova","year":"2015","journal-title":"Nutr J"},{"key":"10.1016\/j.rdc.2018.03.007_bib21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2018.03.007_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-015-0642-1","article-title":"Gout and the risk of dementia: a nationwide population-based cohort study","volume":"17","author":"Hong","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2018.03.007_bib23","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A\u00a0two staged approach to the treatment of hyperuricemia in gout: the \u201cdirty dish\u201d hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.03.007_bib24","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.ajkd.2015.09.002","article-title":"Is it time to start treating asymptomatic hyperuricemia?","volume":"66","author":"Levy","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2018.03.007_bib25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-016-0550-y","article-title":"Lesinurad: first global approval","volume":"76","author":"Hoy","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.rdc.2018.03.007_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2018.03.007_bib27","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2018.03.007_bib28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A\u00a0randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600\u00a0mg\/day versus benzbromarone 100\u2013200\u00a0mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2018.03.007_bib29","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions","volume":"38","author":"Chohan","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2018.03.007_bib30","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2018.03.007_bib31","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2018.03.007_bib32","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1056\/NEJMra1511117","article-title":"Calcium pyrophosphate deposition disease","volume":"374","author":"Rosenthal","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2018.03.007_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neuchi.2013.03.003","article-title":"Eighteen cases of crowned dens syndrome: Presentation and diagnosis","volume":"59","author":"Godfrin-Valnet","year":"2013","journal-title":"Neurochirurgie"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:16:19Z","timestamp":1760181379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X18300322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0889857X18300322"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2018.03.007","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crystal-Induced Arthritides in the Elderly","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2018.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}